Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

David A. Reardon; Alba A. Brandes; Antonio Omuro; Paul Mulholland; Michael Lim; Antje Wick; Joachim Baehring; Manmeet S. Ahluwalia; Patrick Roth; Oliver Bähr; Surasak Phuphanich; Juan Manuel Sepulveda; Paul De Souza; Solmaz Sahebjam; Michael Carleton; Kay Tatsuoka; Corina Taitt; Ricardo Zwirtes; John Sampson; Michael Weller

doi:10.1001/JAMAONCOL.2020.1024

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

David A. Reardon, Alba A. Brandes, Antonio Omuro, Paul Mulholland, Michael Lim, Antje Wick, Joachim Baehring, Manmeet S. Ahluwalia, Patrick Roth, Oliver Bähr, Surasak Phuphanich, Juan Manuel Sepulveda, Paul De Souza, Solmaz Sahebjam, Michael Carleton, Kay Tatsuoka, Corina Taitt, Ricardo Zwirtes, John Sampson, Michael Weller

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	JAMA Oncology
Volume	6
DOIs	https://doi.org/10.1001/JAMAONCOL.2020.1024
State	Published - Jul 1 2020

Disciplines

Medicine and Health Sciences
Oncology
Internal Medicine

Access to Document

10.1001/JAMAONCOL.2020.1024License: Unspecified

Cite this

Reardon, D. A., Brandes, A. A., Omuro, A., Mulholland, P., Lim, M., Wick, A., Baehring, J., Ahluwalia, M. S., Roth, P., Bähr, O., Phuphanich, S., Sepulveda, J. M., De Souza, P., Sahebjam, S., Carleton, M., Tatsuoka, K., Taitt, C., Zwirtes, R., Sampson, J., & Weller, M. (2020). Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial. JAMA Oncology, 6. https://doi.org/10.1001/JAMAONCOL.2020.1024

Reardon, DA, Brandes, AA, Omuro, A, Mulholland, P, Lim, M, Wick, A, Baehring, J, Ahluwalia, MS, Roth, P, Bähr, O, Phuphanich, S, Sepulveda, JM, De Souza, P, Sahebjam, S, Carleton, M, Tatsuoka, K, Taitt, C, Zwirtes, R, Sampson, J & Weller, M 2020, 'Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial', JAMA Oncology, vol. 6. https://doi.org/10.1001/JAMAONCOL.2020.1024

@article{7e37263a489248079c3c61191f07345e,

title = "Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial",

author = "Reardon, \{David A.\} and Brandes, \{Alba A.\} and Antonio Omuro and Paul Mulholland and Michael Lim and Antje Wick and Joachim Baehring and Ahluwalia, \{Manmeet S.\} and Patrick Roth and Oliver B{\"a}hr and Surasak Phuphanich and Sepulveda, \{Juan Manuel\} and \{De Souza\}, Paul and Solmaz Sahebjam and Michael Carleton and Kay Tatsuoka and Corina Taitt and Ricardo Zwirtes and John Sampson and Michael Weller",

year = "2020",

month = jul,

day = "1",

doi = "10.1001/JAMAONCOL.2020.1024",

language = "American English",

volume = "6",

journal = "JAMA Oncology",

}

TY - JOUR

T1 - Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

AU - Reardon, David A.

AU - Brandes, Alba A.

AU - Omuro, Antonio

AU - Mulholland, Paul

AU - Lim, Michael

AU - Wick, Antje

AU - Baehring, Joachim

AU - Ahluwalia, Manmeet S.

AU - Roth, Patrick

AU - Bähr, Oliver

AU - Phuphanich, Surasak

AU - Sepulveda, Juan Manuel

AU - De Souza, Paul

AU - Sahebjam, Solmaz

AU - Carleton, Michael

AU - Tatsuoka, Kay

AU - Taitt, Corina

AU - Zwirtes, Ricardo

AU - Sampson, John

AU - Weller, Michael

PY - 2020/7/1

Y1 - 2020/7/1

UR - https://jamanetwork.com/journals/jamaoncology/fullarticle/2766213

U2 - 10.1001/JAMAONCOL.2020.1024

DO - 10.1001/JAMAONCOL.2020.1024

M3 - Article

VL - 6

JO - JAMA Oncology

JF - JAMA Oncology

ER -

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

Disciplines

Access to Document

Other files and links

Cite this